image credit: Pixabay

Biogen puts down massive $350M upfront for Sangamo preclinical assets

February 28, 2020

A year ago, Sangamo’s shares sank after it posted lackluster data for its genome-editing therapy; 12 months down the line, and it’s a complete reversal for the biotech as Biogen lays down a major upfront and biobucks pact for several of its central nervous system (CNS) meds.

While not the buyout many investors have been hoping for, Biogen is still the white knight for the biotech, which took a big knock in early 2019.

The Big Biotech, which is trying to make Alzheimer’s disease (AD) research great again, is days away (if you believe the analysts) from filing its failed AD drug aducanumab with the FDA.

Read More on FierceBiotech